company background image
TNDM

Tandem Diabetes CareNasdaqGM:TNDM Stock Report

Last Price

US$123.83

Market Cap

US$7.9b

7D

-3.6%

1Y

33.7%

Updated

19 Jan, 2022

Data

Company Financials +
TNDM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

TNDM Stock Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.

Tandem Diabetes Care Competitors

Medtronic

NYSE:MDT

US$144.9b

Becton Dickinson

NYSE:BDX

US$75.2b

DexCom

NasdaqGS:DXCM

US$42.2b

Insulet

NasdaqGS:PODD

US$16.2b

Price History & Performance

Summary of all time highs, changes and price drops for Tandem Diabetes Care
Historical stock prices
Current Share PriceUS$123.83
52 Week HighUS$155.86
52 Week LowUS$76.19
Beta0.38
1 Month Change-15.31%
3 Month Change-2.80%
1 Year Change33.67%
3 Year Change193.65%
5 Year Change358.63%
Change since IPO-35.71%

Recent News & Updates

Jan 03

Tandem Diabetes Care: A Difficult Valuation To Justify

Tandem Diabetes Care has demonstrated significant growth on its top line in recent years and its bottom line has improved drastically. Growth continues through its 2021 fiscal year and it's likely the firm will only grow further in the years to come. But shares look very expensive and even continued growth could make the company's price difficult to justify.

Dec 20
Tandem Diabetes Care (NASDAQ:TNDM) Might Have The Makings Of A Multi-Bagger

Tandem Diabetes Care (NASDAQ:TNDM) Might Have The Makings Of A Multi-Bagger

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

Nov 29
We Think Tandem Diabetes Care (NASDAQ:TNDM) Can Stay On Top Of Its Debt

We Think Tandem Diabetes Care (NASDAQ:TNDM) Can Stay On Top Of Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

TNDMUS Medical EquipmentUS Market
7D-3.6%-4.8%-4.6%
1Y33.7%-0.4%7.7%

Return vs Industry: TNDM exceeded the US Medical Equipment industry which returned 0.8% over the past year.

Return vs Market: TNDM exceeded the US Market which returned 10.2% over the past year.

Price Volatility

Is TNDM's price volatile compared to industry and market?
TNDM volatility
TNDM Average Weekly Movement6.3%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: TNDM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TNDM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20061,500John Sheridanhttps://www.tandemdiabetes.com

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump’s software.

Tandem Diabetes Care Fundamentals Summary

How do Tandem Diabetes Care's earnings and revenue compare to its market cap?
TNDM fundamental statistics
Market CapUS$7.87b
Earnings (TTM)US$21.76m
Revenue (TTM)US$660.87m

361.6x

P/E Ratio

11.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TNDM income statement (TTM)
RevenueUS$660.87m
Cost of RevenueUS$307.83m
Gross ProfitUS$353.04m
ExpensesUS$331.28m
EarningsUS$21.76m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.34
Gross Margin53.42%
Net Profit Margin3.29%
Debt/Equity Ratio72.1%

How did TNDM perform over the long term?

See historical performance and comparison

Valuation

Is Tandem Diabetes Care undervalued compared to its fair value and its price relative to the market?

361.59x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TNDM ($123.83) is trading above our estimate of fair value ($123.51)

Significantly Below Fair Value: TNDM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TNDM is poor value based on its PE Ratio (361.6x) compared to the US Medical Equipment industry average (46.7x).

PE vs Market: TNDM is poor value based on its PE Ratio (361.6x) compared to the US market (17x).


Price to Earnings Growth Ratio

PEG Ratio: TNDM is poor value based on its PEG Ratio (9.4x)


Price to Book Ratio

PB vs Industry: TNDM is overvalued based on its PB Ratio (20.2x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is Tandem Diabetes Care forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

38.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNDM's forecast earnings growth (38.6% per year) is above the savings rate (2%).

Earnings vs Market: TNDM's earnings (38.6% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TNDM's revenue (16.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: TNDM's revenue (16.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TNDM's Return on Equity is forecast to be low in 3 years time (10.9%).


Past Performance

How has Tandem Diabetes Care performed over the past 5 years?

31.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TNDM has high quality earnings.

Growing Profit Margin: TNDM became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: TNDM has become profitable over the past 5 years, growing earnings by 31.1% per year.

Accelerating Growth: TNDM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TNDM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: TNDM's Return on Equity (5.6%) is considered low.


Financial Health

How is Tandem Diabetes Care's financial position?


Financial Position Analysis

Short Term Liabilities: TNDM's short term assets ($754.9M) exceed its short term liabilities ($119.7M).

Long Term Liabilities: TNDM's short term assets ($754.9M) exceed its long term liabilities ($341.0M).


Debt to Equity History and Analysis

Debt Level: TNDM has more cash than its total debt.

Reducing Debt: TNDM's debt to equity ratio has reduced from 887.6% to 72.1% over the past 5 years.

Debt Coverage: TNDM's debt is well covered by operating cash flow (38.1%).

Interest Coverage: TNDM's interest payments on its debt are well covered by EBIT (3.5x coverage).


Balance Sheet


Dividend

What is Tandem Diabetes Care current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TNDM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TNDM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TNDM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TNDM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TNDM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

John Sheridan (66 yo)

8.75yrs

Tenure

US$3,790,739

Compensation

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD3.79M) is below average for companies of similar size in the US market ($USD6.41M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TNDM's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: TNDM's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Tandem Diabetes Care, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Tandem Diabetes Care, Inc.
  • Ticker: TNDM
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$7.867b
  • Shares outstanding: 63.53m
  • Website: https://www.tandemdiabetes.com

Number of Employees


Location

  • Tandem Diabetes Care, Inc.
  • 11075 Roselle Street
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:45
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.